doi: 10.1016/j.chemosphere.2020.128350
While semaglutide has not been proven to cause pancreatitis in healthy users, post-market reports have documented pancreatitis cases during GLP-1 therapy
Solutions like MeAgain centralize dose schedules, injection-site tracking, side-effect logging, and nutrition and hydration records, allowing users to run short, measurable experiments and share clean data with clinicians to resolve issues faster
We review your medical history, perform any necessary testing, calculate your BMI, and discuss your weight loss goals
This means more frequent follow-ups, goal-setting for weight and glucose metrics, and interdisciplinary collaboration
A 2025 RAND survey on GLP-1 use in the United States found that about half of adults on GLP-1 agonists report experiencing nausea